摘要
药品专利期限补偿制度的目的是通过补偿专利期的"不合理占用",实现激励医药产业创新的目的。然而从国外制度实践情况来看,药品专利期限补偿制度并未起到"激励创新"的作用。考虑到专利期限延长将会对药品可及性带来不利影响,中国建立药品专利期限补偿制度时,建议以落实协议最低义务为原则。中美经贸协议对专利期限补偿条件、补偿期限、补偿期限内专利权范围及限制与例外等基本问题作出了规定,美国、欧盟和日本的药品专利期限补偿制度均从这几个方面对药品专利期限补偿进行了限制,这也为中国建立药品专利期限补偿制度提供了参考和借鉴。
The purpose of the pharmaceutical patent term compensation system is to encourage innovation in the phar⁃maceutical industry by compensating for the"unreasonable occupation"of the patent term.However,judging from the practice of foreign systems,the pharmaceutical patent term compensation system has not played the role of"incentive innovation".Considering that the extension of the patent term will adversely affect the accessibility of medicines,when establishing a pharmaceutical patent term compensation system in China,it is recommended that the principle of im⁃plementing the minimum obligations of the agreement be adopted.The China-US Economic and Trade Agreement stip⁃ulates basic issues such as the compensation conditions for the patent period,the length of the compensation period,the scope of patent rights within the period of compensation,and limitations and exceptions.The pharmaceutical patent term compensation systems in the United States,the European Union and Japan define pharmaceutical patent term compensation from these aspects,which provides a reference for China to establish a pharmaceutical patent term com⁃pensation system.
作者
邱福恩
QIU Fu-en(Institute of International Law,Wuhan University,Wuhan 430072,China)
出处
《科技与法律》
CSSCI
2020年第4期11-21,共11页
Science Technology and Law
关键词
中美经贸协议
专利期限补偿
保护范围
药品可及性
China-US Economic and Trade Agreement
patent term compensation
scope of right
accessibility of med⁃icines
